MedPath

ASTRAZENECA PHARMACEUTICALS LP

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.astrazeneca-us.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

79

FDA:40
NMPA:20
PHILIPPINES:10
+1 more agencies

Drug Approvals

Budesonide and Formoterol Fumarate Inhalation Aerosol (III)

Product Name
布地奈德福莫特罗吸入气雾剂(Ⅲ)
Approval Number
国药准字HJ20240069
Approval Date
Jun 28, 2024
NMPA

Quetiapine Fumarate Extended-Release Tablets

Product Name
富马酸喹硫平缓释片
Approval Number
国药准字J20140011
Approval Date
Jun 16, 2020
NMPA

Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (I)

Product Name
安立格
Approval Number
J20171033
Approval Date
Jul 18, 2017
NMPA

Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (II)

Product Name
安立格
Approval Number
国药准字J20171034
Approval Date
Jul 18, 2017
NMPA

Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (III)

Product Name
安立格
Approval Number
国药准字J20171032
Approval Date
Jul 18, 2017
NMPA

Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (I)

Product Name
安立格
Approval Number
国药准字J20171033
Approval Date
Jul 18, 2017
NMPA

Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (II)

Product Name
安立格
Approval Number
J20171034
Approval Date
Jul 18, 2017
NMPA

Saxagliptin and Metformin Hydrochloride Sustained-release Tablets (III)

Product Name
安立格
Approval Number
J20171032
Approval Date
Jul 18, 2017
NMPA

Daclatasvir Hydrochloride Tablets

Product Name
百立泽
Approval Number
J20171011
Approval Date
Jun 16, 2017
NMPA

Daclatasvir Hydrochloride Tablets

Product Name
百立泽
Approval Number
国药准字J20171011
Approval Date
Jun 16, 2017
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.